Takeda Pharmaceutical Co. Ltd. is leading a $125 million investment in Maverick Therapeutics Inc., a company founded with initial financing from MPM Capital that is working to improve the utility of T-cell redirection therapy for the treatment of cancer.
Exclusive rights to Assembly Biosciences Inc.'s preclinical gastrointestinal (GI) microbiome programs and additional GI programs secured with a $50 million up-front from Allergan plc could yield a much bigger payday, the company revealed Tuesday.
SAN FRANCISCO – Moderna Therapeutics Inc. CEO Stéphane Bancel opened the 35th annual J.P. Morgan Healthcare Conference on Monday by unblinding indications and targets for a raft of before-now veiled candidates in the mRNA specialist's pipeline, five of which are now in the clinic, including its Astrazeneca plc-partnered cardiometabolic candidate, AZD-8601.
Vir Biotechnology Inc., a new enterprise pursuing infectious disease therapies with immunology ideas popularized by cancer fighters, is launching under the leadership of departing Biogen Inc. CEO George Scangos. Robert Nelsen, whose Arch Venture Partners is leading a $150 million investment with additional funds coming from the Bill & Melinda Gates Foundation.
Johnson & Johnson Innovation LLC is opening 2017 with a blizzard of new deals, touching depression, cancer, diabetes, obesity and more. Highlights among the deals include an option to buy Bird Rock Bio Inc. following a phase I readout for its non-alcoholic steatohepatitis candidate, namacizumab, and dibs for Janssen Pharmaceuticals Inc. on new fast-acting ketamine analogue antidepressants to be developed with Amorsa Therapeutics Inc. Further deals enlist partners to explore development of RNA-based therapies for cancer and infectious disease and new therapies for prostate cancer, rheumatoid arthritis and metabolic disorders.
Neon Therapeutics Inc., a company developing neoantigen-based therapeutic cancer vaccines and T cell therapies, completed a $70 million series B financing that it said will help it advance its lead candidate, NEO-PV-01, through an ongoing phase Ib clinical trial.
An experimental glaucoma drug developed by Inotek Pharmaceuticals Corp. to augment the eye’s natural method of reducing intraocular pressure (IOP) failed to prove itself better than a placebo at all 12 time points of the pivotal phase III study Matrx-1.
A new drug application (NDA) for Xaracoll, an implantable bupivacaine collagen matrix developed by Innocoll Holdings plc for postsurgical pain relief, must be filed as a drug/device combination product, the FDA said, dashing company hopes for an August 2017 approval.
Quintiles IMS Holdings Inc. has formed a new collaborative initiative with four top biopharma companies to ferret out real-world data on the use of cancer treatments across seven top European markets. The Collaboration for Oncology Data in Europe, or CODE, is funded both by QuintilesIMS and four initial partners with an interest in the data: Bristol-Myers Squibb Co., Eli Lilly and Co., Merck KGaA and Pfizer Inc.
